Skip to main
VVOS
VVOS logo

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics Inc has demonstrated a robust upward trajectory in its revenue, with a year-over-year increase of 17% in Q3 FY24 and 19% in Q2 FY24, culminating in Q3 revenue of $4.1 million. The company's positive momentum is bolstered by anticipated expansions into new locations and the successful introduction of higher pricing strategies following recent FDA clearances. Furthermore, with improved revenue forecasts for FY24, now estimated at $16.3 million, Vivos Therapeutics is positioning itself toward achieving breakeven status by FY2025.

Bears say

Vivos Therapeutics Inc is facing a negative outlook as its FY24 revenue estimate has been reduced to $15.2 million from $16.3 million, indicating potential struggles in sales performance. The pro forma EPS figures are underwhelming, with negative earnings per share identified at $(0.55) and $(0.60) for recent periods, both surpassing estimates and consensus projections, raising concerns regarding profitability and operational efficiency. Additionally, the company faces significant risks including balance sheet and liquidity issues, regulatory hurdles, market competition, and challenges in commercialization and reimbursement, all of which may impede its growth trajectory and overall financial stability.

Vivos Therapeutics (VVOS) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.